Brain Under Siege: XPro™ Emerges as a Powerful New Ally Against TBI-Fueled Alzheimer's!

Traumatic Brain Injury (TBI) ignites a devastating inflammatory firestorm, accelerating the path to Alzheimer's disease.
The revolutionary drug XPro™ intervenes at a critical juncture, neutralizing the key inflammatory culprit, soluble TNF (solTNF).
Groundbreaking animal studies, backed by the Department of Defense, reveal XPro™ dramatically slashes brain amyloid and restores vital neurological function.

The aftermath of a Traumatic Brain Injury (TBI) can be a terrifying countdown to cognitive decline, with Alzheimer’s Disease (AD) looming as a devastating consequence. TBI unleashes a vicious cycle of neuroinflammation, primarily driven by the destructive protein soluble Tumor Necrosis Factor (solTNF) [6, 7]. This inflammatory cascade ignites a molecular firestorm, causing TNF receptor 1 (TNFR1) to surge, which in turn cranks up the enzyme BACE1. BACE1 then relentlessly carves out neurotoxic amyloid beta (Aβ42) plaques – the infamous hallmarks of AD – leading to neuronal death and the erosion of memory [6, 7].

But in a stunning breakthrough, scientists are fighting back. Research spearheaded by INmune Bio, Inc. (NASDAQ: INMB) in collaboration with Virginia Commonwealth University, and supported by the Department of Defense, has unveiled XPro™ (pegipanermin) as a potent weapon against this neurological onslaught. When administered a mere 30 minutes post-injury in animal models at risk for Alzheimer's, XPro™ acted with decisive power. By selectively neutralizing solTNF, it effectively disarmed the solTNF/TNFR1 signaling pathway, halting the catastrophic rise in BACE1, Aβ42, and cell death markers⁷.

The results are nothing short of remarkable: XPro™ significantly curtailed the insidious amyloid accumulation in the hippocampus and markedly improved behavioral and neurological outcomes⁷. Dr. Kirsty Dixon emphasized, “Our findings demonstrate that TBI exacerbates amyloidogenesis and behavioral deficits… through solTNF/TNFR1 signaling,” underscoring XPro™ as a "promising treatment to reduce AD pathology risk post-TBI." With XPro™ already advancing through Phase II clinical trials for Alzheimer's and related conditions [4, 5, 8], this research offers a profound ray of hope for vulnerable populations, including the elderly and military personnel, whose lives are too often darkened by the shadow of TBI-induced dementia. The fight to preserve brain health has gained a formidable new champion. Discover more about INmune Bio’s innovative approach at www.inmunebio.com.

Brain Under Siege: XPro™ Emerges as a Powerful New Ally Against TBI-Fueled Alzheimer's!

References

Stay Updated!